Table 4.
Genome-Wide Association Study Meta-Analysis Results of Subjects with Chronic Obstructive Pulmonary Disease with a Pulmonary Artery:Ascending Aorta Ratio Greater Than 1 versus Smoking Control Subjects Compared with Those of Subjects with Chronic Obstructive Pulmonary Disease with a Pulmonary Artery:Ascending Aorta Ratio of 1 or Less versus Smoking Control Subjects for Previously Identified COPD Risk Alleles
Locus | Gene | SNP | Risk Allele | COPD with PA/A > 1 versus Smoking Control Subjects |
COPD with PA/A ≤ 1 versus Smoking Control Subjects |
Permutation Testing to Assess Difference of OR between Two Meta-Analyses, 10,000 Times | ||
---|---|---|---|---|---|---|---|---|
OR | P Value | OR | P Value | P Value | ||||
4q22 | FAM13A | rs2869967* | C | 1.25 | 9.14 × 10−5 | 1.28 | 8.73 × 10−10 | NS |
4q22 | FAM13A | rs4416442† | C | 1.27 | 1.66 × 10−5 | 1.28 | 1.74 × 10−10 | NS |
4q22 | FAM13A | rs7671167*,‡ | T | 1.25 | 7.39 × 10−5 | 1.22 | 2.32 × 10−7 | NS |
4q22 | FAM13A | rs1964516‡ | T | 1.17 | 6.32 × 10−3 | 1.23 | 2.38 × 10−7 | 0.015 |
4q31 | HHIP | rs13141641†,‡ | T | 1.28 | 5.68 × 10−5 | 1.23 | 7.94 × 10−7 | 0.013 |
4q31 | HHIP | rs13118928‡ | A | 1.22 | 9.25 × 10−4 | 1.21 | 4.25 × 10−6 | NS |
15q25 | CHRNA3 | rs12914385† | T | 1.36 | 1.61 × 10−7 | 1.23 | 5.98 × 10−7 | <0.0001 |
15q25 | AGPHD1 | rs8034191§ | C | 1.40 | 7.80 × 10−9 | 1.12 | 7.97 × 10−3 | <0.0001 |
15q25 | IREB2 | rs11858836‡ | A | 1.38 | 3.90 × 10−7 | 1.16 | 1.32 × 10−3 | <0.0001 |
19q13 | RAB4B | rs2604894‡ | G | 1.16 | 1.01 × 10−2 | 1.10 | 1.53 × 10−2 | 0.010 |
14q32 | RIN3 | rs754388† | C | 1.38 | 3.49 × 10−5 | 1.29 | 1.19 × 10−6 | 0.007 |
14q32 | RIN3 | rs17184313† | C | 1.27 | 2.15 × 10−3 | 1.27 | 8.53 × 10−6 | NS |
Definition of abbreviations: COPD, chronic obstructive pulmonary disease; NS, not significant; OR, odds ratio; PA/A, ratio of the diameter of the main pulmonary artery (PA) at the level of its bifurcation and the diameter of the ascending aorta (A) in its maximum dimension measured by computed tomography; SNP, single-nucleotide polymorphism.
Cho and colleagues (Ref. 27).
Cho and colleagues (Ref. 23).
Cho and colleagues (Ref. 29).
Pillai and colleagues (Ref. 37).